Prevention and management of viral hepatitis in inflammatory bowel disease: A clinical practice guideline by the korean association for the study of intestinal diseases

for the IBD Research Group of the Korean Association for the Study of Intestinal Diseases

doi:10.5217/ir.2019.09155

Prevention and management of viral hepatitis in inflammatory bowel disease: A clinical practice guideline by the korean association for the study of intestinal diseases

for the IBD Research Group of the Korean Association for the Study of Intestinal Diseases

Research output: Contribution to journal › Review article › peer-review

15 Citations (Scopus)

Abstract

The treatment of inflammatory bowel disease (IBD) has been revolutionized for the last 10 years by the increasing use of immunomodulators and biologics. With immunosuppression of this kind, opportunistic infection is an important safety concern for patients with IBD. In particular, viral hepatitis is determined by the interaction between the virus and the host's immunity, and the risk of reactivation increases if immunity is compromised by immunosuppression therapy. Parts of Asia, including Korea, still show intermediate endemicity for the hepatitis A virus and hepatitis B virus compared with the United States and Western Europe. Thus, members of IBD research group of the Korean Association for the Study of Intestinal Diseases have produced a guideline on the prevention and management of viral hepatitis in IBD.

Original language	English
Pages (from-to)	18-33
Number of pages	16
Journal	Intestinal Research
Volume	18
Issue number	1
DOIs	https://doi.org/10.5217/ir.2019.09155
Publication status	Published - 2020 Jan 1

Bibliographical note

Funding Information:
We thank members of the Korean Association for the Study of Intestinal Diseases (KASID) and Korean Association for the Study of the Liver (KASL) for their contribution to the agreement voting and reviewing the manuscript.

Publisher Copyright:
© 2020. Korean Association for the Study of Intestinal Diseases.

Keywords

Inflammatory bowel disease
Prevention
Vaccination
Viral hepatitis

ASJC Scopus subject areas

Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.5217/ir.2019.09155

Cite this

Prevention and management of viral hepatitis in inflammatory bowel disease: A clinical practice guideline by the korean association for the study of intestinal diseases. / for the IBD Research Group of the Korean Association for the Study of Intestinal Diseases.
In: Intestinal Research, Vol. 18, No. 1, 01.01.2020, p. 18-33.

Research output: Contribution to journal › Review article › peer-review

@article{dd198ad400b148498d64936434bc4e92,

title = "Prevention and management of viral hepatitis in inflammatory bowel disease: A clinical practice guideline by the korean association for the study of intestinal diseases",

abstract = "The treatment of inflammatory bowel disease (IBD) has been revolutionized for the last 10 years by the increasing use of immunomodulators and biologics. With immunosuppression of this kind, opportunistic infection is an important safety concern for patients with IBD. In particular, viral hepatitis is determined by the interaction between the virus and the host's immunity, and the risk of reactivation increases if immunity is compromised by immunosuppression therapy. Parts of Asia, including Korea, still show intermediate endemicity for the hepatitis A virus and hepatitis B virus compared with the United States and Western Europe. Thus, members of IBD research group of the Korean Association for the Study of Intestinal Diseases have produced a guideline on the prevention and management of viral hepatitis in IBD.",

keywords = "Inflammatory bowel disease, Prevention, Vaccination, Viral hepatitis",

author = "{for the IBD Research Group of the Korean Association for the Study of Intestinal Diseases} and Park, {Soo Kyung} and Choi, {Chang Hwan} and Jaeyoung Chun and Heeyoung Lee and Kim, {Eun Sun} and Park, {Jae Jun} and Park, {Chan Hyuk} and Lee, {Bo In} and Yunho Jung and Park, {Dong Il} and Kim, {Do Young} and Hana Park and Jeen, {Yoon Tae}",

note = "Funding Information: We thank members of the Korean Association for the Study of Intestinal Diseases (KASID) and Korean Association for the Study of the Liver (KASL) for their contribution to the agreement voting and reviewing the manuscript. Publisher Copyright: {\textcopyright} 2020. Korean Association for the Study of Intestinal Diseases.",

year = "2020",

month = jan,

day = "1",

doi = "10.5217/ir.2019.09155",

language = "English",

volume = "18",

pages = "18--33",

journal = "Intestinal Research",

issn = "1598-9100",

publisher = "Korean Association for the Study of Intestinal Diseases",

number = "1",

}

TY - JOUR

T1 - Prevention and management of viral hepatitis in inflammatory bowel disease

T2 - A clinical practice guideline by the korean association for the study of intestinal diseases

AU - for the IBD Research Group of the Korean Association for the Study of Intestinal Diseases

AU - Park, Soo Kyung

AU - Choi, Chang Hwan

AU - Chun, Jaeyoung

AU - Lee, Heeyoung

AU - Kim, Eun Sun

AU - Park, Jae Jun

AU - Park, Chan Hyuk

AU - Lee, Bo In

AU - Jung, Yunho

AU - Park, Dong Il

AU - Kim, Do Young

AU - Park, Hana

AU - Jeen, Yoon Tae

N1 - Funding Information: We thank members of the Korean Association for the Study of Intestinal Diseases (KASID) and Korean Association for the Study of the Liver (KASL) for their contribution to the agreement voting and reviewing the manuscript. Publisher Copyright: © 2020. Korean Association for the Study of Intestinal Diseases.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - The treatment of inflammatory bowel disease (IBD) has been revolutionized for the last 10 years by the increasing use of immunomodulators and biologics. With immunosuppression of this kind, opportunistic infection is an important safety concern for patients with IBD. In particular, viral hepatitis is determined by the interaction between the virus and the host's immunity, and the risk of reactivation increases if immunity is compromised by immunosuppression therapy. Parts of Asia, including Korea, still show intermediate endemicity for the hepatitis A virus and hepatitis B virus compared with the United States and Western Europe. Thus, members of IBD research group of the Korean Association for the Study of Intestinal Diseases have produced a guideline on the prevention and management of viral hepatitis in IBD.

AB - The treatment of inflammatory bowel disease (IBD) has been revolutionized for the last 10 years by the increasing use of immunomodulators and biologics. With immunosuppression of this kind, opportunistic infection is an important safety concern for patients with IBD. In particular, viral hepatitis is determined by the interaction between the virus and the host's immunity, and the risk of reactivation increases if immunity is compromised by immunosuppression therapy. Parts of Asia, including Korea, still show intermediate endemicity for the hepatitis A virus and hepatitis B virus compared with the United States and Western Europe. Thus, members of IBD research group of the Korean Association for the Study of Intestinal Diseases have produced a guideline on the prevention and management of viral hepatitis in IBD.

KW - Inflammatory bowel disease

KW - Prevention

KW - Vaccination

KW - Viral hepatitis

UR - http://www.scopus.com/inward/record.url?scp=85079740256&partnerID=8YFLogxK

U2 - 10.5217/ir.2019.09155

DO - 10.5217/ir.2019.09155

M3 - Review article

AN - SCOPUS:85079740256

SN - 1598-9100

VL - 18

SP - 18

EP - 33

JO - Intestinal Research

JF - Intestinal Research

IS - 1

ER -

Prevention and management of viral hepatitis in inflammatory bowel disease: A clinical practice guideline by the korean association for the study of intestinal diseases

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this